Gerresheimer Sets up New Production Facility for Insulin Pen Systems in Brazil
Insulin pens are drug-delivery devices in ball-point pen format whichallow diabetes patients to inject themselves with the regularly requiredinsulin dose safely and almost painlessly. Novo Nordisk as the world'sleading insulin producer has contracted Gerresheimer to manufacturecomponents for its insulin pens. Novo Nordisk has a large insulin plant inBrazil which will in future be supplied locally by the new technology centerof the Gerresheimer Group. For Gerresheimer this is already the fourthproduction plant in South America in addition to two existing plants forstandardized pharma plastic packaging in Brazil and one in Argentina.
Apart from the new production facility in Brazil, Gerresheimer alreadyhas two other production facilities for pen systems in Europe.
"Cooperation with Novo Nordisk in Brazil is of substantial strategicimportance for us. We support the customer in developing new markets and atthe same time expand our technological base in South America," saysGerresheimer CEO Dr. Axel Herberg.
Gerresheimer employs around 10,000 people in 40 locations in Europe,America and Asia. In the financial year 2008, worldwide sales totaledEUR1.06bn. The product portfolio ranges from pharma-ceu-tical vials made ofglass and plastic through to complex drug-delivery systems for the pharma &healthcare industry. These include sterile syringes, inhalers and othersystem-based approaches for safe dosage and application of medications. TheGroup enjoys a leading position in markets which are characterized by hightechnical and regulatory barriers.DUSSELDORF, Germany, January 11 /PRNewswire-FirstCall/ -- - Expansion of Cooperation With Diabetes Leader Novo Nordisk - Important Step in the Worldwide Development of Medical Plastic Systems
SOURCE Gerresheimer AG
You May Also Like